Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (DE:41X)
FRANKFURT:41X
Holding DE:41X?
Track your performance easily
41X Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.09 - €9.12
Previous Close€5.37
Volume0.00
Average Volume (3M)1.59K
Market Cap
€1.28B
Enterprise Value€1.21B
Total Cash (Recent Filing)$185.96M
Total Debt (Recent Filing)$104.89M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 07, 2024EPS Estimate
-€0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding235,428,183
10 Day Avg. Volume1,502
30 Day Avg. Volume1,592
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)8.66
Price to Sales (P/S)6.68
Price to Cash Flow (P/CF)-18.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.75
Enterprise Value/Gross Profit11.33
Enterprise Value/Ebitda-25.95
Forecast
1Y Price Target
€9.57Price Target Upside78.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ardelyx News
Bulls Say, Bears Say
Bulls Say
Market Confidence And ValuationThe analyst maintains a Buy rating for the stock with a $10 price target, suggesting that despite the current challenges, the stock is considered undervalued and presents a significant upside potential if key strategies are successful.
Strong Revenue GrowthArdelyx reported a 2Q24 total revenues top line beat of $73.2M, which was approximately 33% above FactSet consensus estimates, exhibiting strong growth for both Ibsrela in IBS-C and their newer product Xphozah for hyperphosphatemia.
Successful Product LaunchThe Xphozah launch continued to show strong momentum, with 2Q24 Xphozah revenues of $37.1M coming in significantly above consensus estimates, driven by strong early demand from nephrology prescribers and a highly aware US market.
Bears Say
Legal IssuesArdelyx's lawsuit against the CMS is expected to create significant legal expenses and management distraction, potentially leading to uncertainty around the stock.
Reimbursement Challenges2025 may present unique headwinds with Xphozah reimbursement changes.
Strategic DecisionsARDX’s decision to not apply for Transitional Drug Add-on Payment Adjustment (TDAPA) reimbursement for Xphozah under CMS’ planned ESRD prospective “bundle” payment system came as somewhat of a surprise.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.41% Insiders
19.81% Mutual Funds
0.02% Other Institutional Investors
64.18% Public Companies and
Individual Investors
41X FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was €3.09 and its highest was €9.12 in the past 12 months.
What is Ardelyx’s market cap?
Currently, no data Available
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Nov 07, 2024 which is in 28 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Aug 01, 2024. The company reported -€0.064 earnings per share for the quarter, beating the consensus estimate of -€0.097 by €0.033.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -€0.04.
How many shares outstanding does Ardelyx have?
Ardelyx has 235,428,180 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of -€0.064 in its last earnings report, beating expectations of -€0.097. Following the earnings report the stock price went up 6.457%.
Which hedge fund is a major shareholder of Ardelyx?
Among the largest hedge funds holding Ardelyx’s share is Oracle Investment Management Inc. It holds Ardelyx’s shares valued at 11M.
---
Ardelyx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.57 (78.11% Upside)
€9.57 (78.11% Upside)
Blogger Sentiment
Bullish
DE:41X Sentiment 96%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $520.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
48.23%
12-Months-Change
Fundamentals
Return on Equity
-48.23%
Trailing 12-Months
Asset Growth
62.63%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
41X Earnings Call
Q2 2024
0:00 / 0:00
---
41X Stock 12 Month Forecast
Average Price Target
€9.57
▲(78.11% Upside)
Technical Analysis
Ardelyx
―
Karyopharm Therapeutics
―
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Best Analysts Covering 41X
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+9.57%
reiterated a buy rating 3 months ago
Copying Matthew Kaplan's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +9.57% per trade.
---